Regression discontinuity analysis of Gavi's impact on vaccination rates - ScienceDirect

Since 2001, an aid consortium known as Gavi has accounted for over half of vaccines purchased in the 75 eligible countries with an initial GNI below $1,000 per capita. Regression discontinuity estimates suggest most aid for cheap, existing vaccines like hepatitis B and DPT was inframarginal: for instance, hepatitis B doses sufficient to vaccinate roughly 75% of infants raised vaccination rates by single-digit margins. These results are driven by middle-income countries near the eligibility threshold, and do not preclude larger gains for the poorest countries, global externalities via vaccine markets, or impacts on newer vaccines such as pneumococcal or rotavirus for which income eligibility rules were relaxed. Beginning in 2000, a wide array of public and private aid donors pooled funds to increase immunization rates in poor countries through the primary vehicle of bulk purchase of vaccines. This partnership, Gavi, the Vaccine Alliance, has cumulatively disbursed $13 billion worth of v

Since 2001, an aid consortium known as Gavi has accounted for over half of vaccines purchased in the 75 eligible countries with an initial GNI below $1,000 per capita. Regression discontinuity estimates suggest most aid for cheap, existing vaccines like hepatitis B and DPT was inframarginal: for instance, hepatitis B doses sufficient to vaccinate roughly 75% of infants raised vaccination rates by single-digit margins. These results are driven by middle-income countries near the eligibility threshold, and do not preclude larger gains for the poorest countries, global externalities via vaccine m